ENDPOINTS

Exelixis’ cancer drug wins approval for neuroendocrine tumors

The FDA has approved Exelixis' cancer drug Cabometyx to treat advanced neuroendocrine tumors inside and outside of the pancreas, marking two new indications for the company’s primary source of revenue. The new label includes adults ...

Mar 26, 2025 - 19:32
 0
Exelixis’ cancer drug wins approval for neuroendocrine tumors
The FDA has approved Exelixis' cancer drug Cabometyx to treat advanced neuroendocrine tumors inside and outside of the pancreas, marking two new indications for the company’s primary source of revenue. The new label includes adults ...
Read More

Tags:

Previous Article

Amateur metal detector uncovers massive Iron Age treasure hoard

Next Article

Archaeologists may have finally discovered famous 'lost' canal built by Julius C...

Related Posts

Alnylam appears to win approval for ATTR-CM, setting up competition with Pfizer and BridgeBio

Alnylam appears to win approval for ATTR-CM, setting up...

Mar 20, 2025  0

Lilly-partnered Fauna Bio plans $40M Series A to get into heart failure

Lilly-partnered Fauna Bio plans $40M Series A to get in...

Mar 14, 2025  0

Deerfield sues Alcon over alleged scheme to obstruct Aurion's IPO

Deerfield sues Alcon over alleged scheme to obstruct Au...

Feb 24, 2025  0